Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study

Table 2 Factors associated with withdrawal of peginterferon-α and ribavirin treatment in chronic hepatitis C patients

		Groups		Univariate analysis		Multivariate analysis
Factors		Treatment accomplishment	Treatment withdrawal	Coefficient	P-value	B	Odds ratio	95 % C.I.
Gender (Male/Female)		5824/5766	1184/1226	1.004	0.325	0.000	1.000	0.911–1.099
Age (≥65 years/<65 years)		3146/8423	930/1473	127.536	<0.001	−0.326	0.722	0.651–0.800
History of IFN treatment (naive/experienced)		8463/2928	1716/657	4.005	0.047	0.032	1.033	0.929–1.147
Genotype (1/2 + 3)		7326/4050	1953/397	311.818	<0.001	−1.007	0.365	0.324–0.412
Viral load (high/low)		10713/817	2248/141	4.327	0.038	−0.091	0.913	0.750–1.112
Pre-AST (U/L)^a		43 [30–68] (n = 11511)	48 [34–73] (n = 2385)		<0.001	0.001	1.001	1.000–1.003
Pre-ALT (U/L)^a		51 [31–87] (n = 11517)	52 [34–81] (n = 2384)		0.517
Pre-PLT (x10⁴/μL)		16.0 [13.0–20.0]	15.0 [12.0–19.0]		<0.001	0.001	1.001	0.990–1.013
Pre-PLT (x10⁴/μL)		(n = 11381)	(n = 2349)		<0.001	0.001	1.001	0.990–1.013
FIB-4 index		2.26 [1.48–3.42]	2.84 [1.84–4.28]		<0.001	−0.125	0.882	0.850–0.916
FIB-4 index		(n = 11349)	(n = 2341)		<0.001	−0.125	0.882	0.850–0.916
Year of starting treatment	– 2008	4624	804				Reference
	2009	2845	588	45.561	<0.001	−0.219	0.803	0.710–0.909
	2010–	4119	1015			−0.496	0.609	0.545–0.680
Region	Hokkaido/Tohoku	1404	318			−0.242	0.785	0.666–0.925
	Kanto	793	124			0.180	1.197	0.958–1.497
	Shin-etsu	528	114			0.020	1.020	0.802–1.297
	Hokuriku	717	148			0.036	1.037	0.838–1.283
	Tokai	814	145	20.418	0.009	0.231	1.260	1.019–1.558
	Kinki	2385	544			−0.048	0.953	0.827–1.098
	Chugoku	1890	380			0.006	1.006	0.864–1.172
	Shikoku	476	115			−0.240	0.787	0.619–0.999
	Kyushu	2589	522				Reference

The values of pre-AST, pre-ALT, pre-PLT, and FIB-4 index are shown as median [interquartile range]
^aSince pre-AST and pre-ALT were closely correlated (r = 0.872; P < 0.001), only pre-AST was included in multivariate analysis. Significant factors by multivariate analysis are shown in bold. The patients whose treatment performance could not be determined were excluded from this analysis (n = 55)
ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; C.I., Confidence interval; FIB-4, Fibrosis-4; IFN, Interferon; PLT, Platelets; SVR, Sustained virological response

ISSN: 1471-2458